Next |
home / stock / nrbo / nrbo message board
Subject | By | Source | When |
---|---|---|---|
here we go bulls news is here | db101 | investorshub | 01/31/2024 11:30:13 PM |
Price now last up | SmellMyFinger | investorshub | 01/31/2024 11:04:25 PM |
$NRBO short squeeze signal | reena969 | investorshub | 01/31/2024 7:51:08 PM |
Thoughts on where this is headed? | tw0122 | investorshub | 01/31/2024 3:47:01 PM |
The now | PennyPusher786 | investorshub | 01/31/2024 10:22:13 AM |
The gaining last up | tw0122 | investorshub | 01/31/2024 9:51:27 AM |
The gaining up | tw0122 | investorshub | 01/31/2024 2:56:21 AM |
$NRBO what does this mean? | PENNY DIPZ | investorshub | 01/30/2024 9:38:14 PM |
and the shorts continue | friendVA | investorshub | 01/30/2024 6:11:35 PM |
$NRBO just the news we needed | gr8investment | investorshub | 01/30/2024 9:48:27 AM |
$NRBO Price now | SmellMyFinger | investorshub | 01/30/2024 6:44:36 AM |
$NRBO here we go bulls news is here | tw0122 | investorshub | 01/30/2024 4:47:18 AM |
short squeeze all day | glens0 | investorshub | 01/29/2024 10:31:53 PM |
$NRBO Price now last up | BesaoT35 | investorshub | 01/29/2024 6:07:23 PM |
$NRBO The gaining | tw0122 | investorshub | 01/29/2024 5:03:19 PM |
great news | SmellMyFinger | investorshub | 01/29/2024 1:01:54 PM |
Have a look at this | PennyPusher786 | investorshub | 01/29/2024 12:57:55 PM |
MomentumIts now | reena969 | investorshub | 01/29/2024 11:47:24 AM |
$NRBO great article | tw0122 | investorshub | 01/29/2024 10:36:35 AM |
$NRBO best news of the day | tw0122 | investorshub | 01/29/2024 3:32:25 AM |
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the ...
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire Full Data Readout Expected in the Second Half of 2024 CAMBRIDGE, Mass. , April 1 , 2024 /PRNewswire/ -- Neur...
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update PR Newswire Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to ...